Test and Treat HIV and Viral Hepatitis for Most at Risk Populations in Central and Southeast Asia

Phase 4

Recruiting

• Conditions: A key focus of the study is Hepatitis C, but HIV, hepatiti s B , STI, and TB arealso included.The target population is people who currently inject or use drugs orpreviously injected or used drugs, as well as at other high-risk groups; People Who Inject Drugs; Hepatitis C; HIV; Hepatitis B; TB; STI

• Registration Number: TCTR20220516003
• Lead Sponsor: Dreamlopments Foundation

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-05-16
• Last Update Posted: 19 August 2024
• Study Completion: 2026-06-30

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 4800

Inclusion Criteria

Male, female, or transgender person.
Aged 18 years old or older.
Former or active injecting or non-injecting drug user. PWID/PWUD are expected to represent the largest sub-population of participants enrolling in the study.
Men-who-have-se-with-men (MSM).
Sexual or life partner of a current or former drug user, or other high-risk group (MSM, TG women).
Consenting to participate in the study.
Willing to undertake at least HIV Ab testing and/or HCV Ab testing. Candidates with evidence (written medical/laboratory report) of prior testing (including positive testing) for HIV, HCV, HBV, STI, or LTBI infection can also enroll into the cohort study.
Consenting to participant in the study

Exclusion Criteria

Inability, in the opinion of the study staff, to provide an informed consent decision to participate in the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Baseline prevalence of HCV, HBV and HIV in the study population. 48 months Proportion,Proportion of HIV-infected PWID/PWUD, other high-risk groups and partners, eligible for ART, who have initiated ART, remain in care and have HIV suppression at the end of study. 48 months Propotion,Proportion of participants with active HCV infection initiating therapy who achieve Sustained Virological Response (SVR) 12 weeks after end of therapy. 24 weeks Propotion